SCHEMBL7123529

SCHEMBL7123529

Cc1cc(NC(=O)Cc2cc(C(=N)N)ccc2O)ccc1C(=O)N1CCCCC1CNC(=O)OC(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
F10 P00742 5/20 0.39
PRSS1 P07477 3/20 0.39
ACHE P22303 2/20 0.39
BACE1 P56817 2/20 0.39
ANO1 Q5XXA6 6/20 0.38
HPN P05981 1/20 0.35
HSD11B1 P28845 1/20 0.35
HCRTR1 O43613 2/20 0.35
HCRTR2 O43614 2/20 0.35
RAB9A P51151 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
F2 P00734 1/20 0.34
RHOC P08134 1/20 0.34
RHOA P61586 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7114852 0.99 F10 (0.39) F10PRSS1ACHEBACE1ANO1
SCHEMBL5099780 0.80 F10 (0.42) F10PRSS1HSD11B1F2
SCHEMBL7123492 0.80 MET (0.36) HSD11B1HCRTR1HCRTR2
Hydrochloric Acid SCHEMBL5091399 0.80 F10 (0.42) F10PRSS1HSD11B1F2
SCHEMBL7525319 0.80 F10 (0.42) F10PRSS1ANO1HPNHSD11B1
SCHEMBL2997836 0.79 F10 (0.55) F10PRSS1ANO1HSD11B1RAB9A
Hydrochloric Acid SCHEMBL7124790 0.79 F10 (0.41) F10PRSS1ANO1HPNHSD11B1
SCHEMBL5094210 0.79 F10 (0.54) F10PRSS1ANO1HSD11B1RAB9A
Hydrochloric Acid SCHEMBL5089043 0.79 F10 (0.54) F10PRSS1ANO1HSD11B1RAB9A
Hydrochloric Acid SCHEMBL5099667 0.78 F10 (0.53) F10PRSS1ANO1HSD11B1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020151595-A1 Carboxylic acid amides having antithrombotic activity BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-10-17 US claimed
EP-1360170-A1 CARBOXYLIC AMIDES, THE PRODUCTION AND USE THEREOF AS MEDICAMENTS Boehringer Ingelheim Pharma GmbH & Co.KG (DE) 2003-11-12 EP disclosed
US-20020151595-A1 Carboxylic acid amides having antithrombotic activity BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-10-17 US disclosed
US-20020151595-A1 Carboxylic acid amides having antithrombotic activity BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-10-17 US disclosed
WO-2002062748-A1 CARBOXYLIC AMIDES, THE PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-08-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020151595-A1 Carboxylic acid amides having antithrombotic activity SERPINC1, TFPI, F2 F10 30/4885PRSS1 879/4885ACHE 781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.